AimwellBio Grading System · v1.0

The industry standard for verified intelligence.

Our proprietary 7-point grading system evaluates the confidence, impact, and reliability of every biopharma signal — so you can decide with certainty. Every grade is evidence-backed, source-traced, and audit-ready.

Signal

Ingest the world.

Validation

Verify with rigor.

Decision

Act with confidence.

The AimwellBio Grade Scale

Seven grades. One standard.

Each grade is the result of multi-layer analysis across seven dimensions. The result is a single character — G1 through G7 — that any analyst, regulator, or board member can act on in seconds.

Critical Risk

Severe risk · action required immediately

High Risk

High risk · immediate attention

Elevated Risk

Moderate risk · closely monitor

Neutral

Balanced · no material impact detected

Positive

Favorable signal · monitor opportunity

Highly Positive

Strong positive indicator · act strategically

Very High Confidence

Near-certain outcome · high conviction

← Increasing Risk Neutral Increasing Opportunity →

How grades are determined

Seven dimensions of analysis.

Every grade is the result of a multi-layer evaluation across the dimensions that actually predict regulatory, clinical, and financial outcomes. No vibes. No black boxes.

i · 01

Regulatory Impact

FDA / EMA / global agency posture, guidance trajectory, AdComm signal.

i · 02

Clinical Impact

Endpoint quality, effect size, patient population, comparator strength.

i · 03

Financial Impact

Run-rate exposure, market repricing potential, capital allocation consequence.

i · 04

Data Reliability

Study design rigor, replication, sample size, conflict of interest exposure.

i · 05

Source Quality

Primary vs. secondary, peer review, regulator-grade vs. press-release-grade.

i · 06

Signal Consensus

Cross-source agreement — PubMed, ClinicalTrials.gov, FDA, SEC, EMA.

i · 07

Time Sensitivity

How fast the underlying signal is decaying or compounding.

Every grade. Every time.

Backed. Traced. Audit-ready.

Backed by evidence

Every G-grade points to the underlying signals, studies, and filings. Click through to the source on demand.

Source-traced

Each driver carries its citation. Failed citation resolution automatically downgrades the grade — no exceptions.

Audit-ready

Each grade ships with a tamper-evident signature. Bring our verdicts into a board pack, an FDA filing, an IC memo — they hold up.

Example output

What a grade looks like.

This is the report header a member sees on every graded signal. Same artifact, whether you're reviewing one entity or scanning a thousand.

AimwellBio

SIG-2026-05-12-7421

High Risk

Confidence: 87%

Impact Summary

High regulatory and clinical impact detected.

Key Drivers

FDA guidance change
Safety signal escalation

Programmatic access

Wire your stack to the grade.

Pull graded intelligence directly into dashboards, IC memos, regulatory submissions, or downstream agents. One endpoint. One contract. Stable schema.

// GET https://api.aimwellbio.com/v1/intelligence/grade Authorization: Bearer {your_api_key} Content-Type: application/json // Sample response { "signal_id": "SIG-2026-05-12-7421", "grade": "G2", "grade_label": "HIGH RISK", "confidence_score": 0.87, "impact_summary": "High regulatory and clinical impact detected.", "drivers": ["FDA guidance change", "Safety signal escalation"], "dimensions": { "regulatory_impact": 0.92, "clinical_impact": 0.85, "financial_impact": 0.78, "data_reliability": 0.90, "source_quality": 0.88, "signal_consensus": 0.83, "time_sensitivity": 0.91 }, "evidence_count": 24, "sources": ["FDA.gov", "ClinicalTrials.gov", "EMA.europa.eu"], "timestamp": "2026-05-12T14:32:11Z", "aimwell_signature": "A1B7F9…E3C2" }